Takeda Canada Co-sponsors Grant to Advance IBD Clinical Research
• Takeda Canada co-sponsored a C$1 million grant to the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) to enhance IBD clinical research.
• The CIRC PIONEER Grant was awarded to Dr. Kevan Jacobson and Dr. Genelle Lunken for their dietary intervention study in pediatric Crohn's disease patients.
• The study, DISPENSE-T, will investigate the impact of dietary intervention in Crohn's disease patients initiating anti-TNF therapy.
• Takeda's contribution of C$500,000 underscores its commitment to advancing scientific research and improving outcomes for over 322,000 Canadians affected by IBD.
Health Canada Approves Daybue (Trofinetide) as First Treatment for Rett Syndrome
• Health Canada has approved Daybue (trofinetide) for treating Rett syndrome in patients aged two years and older, marking the first approved treatment for the condition in Canada.
• The approval was based on Phase 3 LAVENDER study results, which demonstrated significant improvements in behavior and communication compared to placebo over a 12-week period.
• Daybue, developed by Acadia Pharmaceuticals, is a synthetic analog of insulin-like growth factor 1, administered orally to lessen inflammation and promote nerve cell connections.
• Experts welcome Daybue as a crucial advancement, offering a specific therapeutic option beyond symptomatic management for Rett syndrome, a neurodevelopmental disorder affecting primarily females.
© Copyright 2025. All Rights Reserved by MedPath